Dear Chairman Leibowitz:

We from the Louisiana Lupus Foundation are writing today to express our concerns with the proposed Express Scripts, Inc./Medco Health Solutions merger. We are especially concerned about what this merger may mean for patient choice and access to specialty pharmaceuticals, and we ask that the Commission carefully examine the impact of the merger in the specialty pharmacy market.

The Louisiana Lupus Foundation is a non-profit entity that strives to provide information, education, and referrals for those affected by lupus, to support public policy and research that promote the treatment, cure, and prevention of lupus, and to promote public education and awareness of the disease.

There are an estimated 1.5 million Americans living with lupus today. Lupus is a chronic, autoimmune disease that can damage any part of the body including skin, joints, or organs inside the body. Lupus is a disease of flares and remissions and can range from mild to life-threatening. With good medical care and strong adherence to the proper medications, most people with lupus can keep their condition under control and lead a full life.

The proposed merger of Express Scripts and Medco would combine two of the three largest pharmacy benefit managers. It would create a mega-PBM with nearly 70 million more covered lives than the next biggest PBM. It would also merge the two largest specialty pharmacies—Express Scripts’ Cura Script Pharmacy and Medco’s Accredia—giving Express Scripts-Medco a 52% share of the specialty pharmacy market.

We are concerned that the merger may harm lupus patients by denying them choices in pharmacy and diminishing their access to critical medications. The extreme dominance of Express Scripts-Medco in the PBM and specialty pharmacy markets will likely increase the incentive and ability for the company to restrict network access and engage in exclusive distribution arrangements that drive patients away from their pharmacy of choice and into their captive mail-order services. Such restrictions deny patients choice, negatively impact patient adherence, lead to disruptions in the continuity of care, and significantly limit access for certain patients, especially those living in rural areas. As lupus patients often must manage multiple, complex medications and need to remain strictly adherent in order to protect their health, pharmacy choice and continuity of care, are of great importance to lupus patients.

12090 S. Harrell’s Ferry Road, Suite Q, Baton Rouge, LA 70816
225-293-3442- 888-GO-LUPUS- 225-775-0222 (Fax)
The Louisiana Lupus Foundation wants to assure that lupus patients have continued choices as to how and where they receive their medications, as well as which medications they have access to. We thank the Commission for carefully considering the concerns of lupus patients nationwide as they investigate the proposed merger of Express Scripts and Medco.

Thank you for considering our concerns.

Sincerely,

Ann Perkins
President
Louisiana Lupus Foundation

cc: Commissioner Brill
    Commissioner Ramirez
    Commissioner Rosch
    Mr. Joe Farrell
    Mr. Rich Feinsteing
    Mr. Jim Southworth